Skip to main content

EHA 2020 - Multiple Myeloma

In newly diagnosed transplant-eligible multiple myeloma patients who achieved very good partial response or better in the Italian FORTE study, there was strong concordance among 3 minimal residual disease–assessing techniques. Read More ›

Induction with ixazomib, daratumumab, and low-dose dexamethasone in frail elderly newly diagnosed multiple myeloma patients in the HOVON 143 study was meaningfully effective regarding ORR and PFS, but with continued toxicity concerns. Read More ›

Adding elotuzumab to bortezomib/lenalidomide/dexamethasone as induction therapy for newly diagnosed multiple myeloma patients in the GMMG-HD6 study failed to increase the rates of very good partial response and complete response after 4 cycles. Read More ›

A retrospective analysis of ICARIA-MM and TCD14079 studies shows adding isatuximab to pomalidomide-dexamethasone improved progression-free survival and increased rates of overall response and very good partial response or better in patients with gain(1q21). Read More ›

Adding isatuximab to pomalidomide-dexamethasone treatment in RRMM patients with preexisting plasmacytomas resulted in improved median progression-free survival and rates of overall response and very good partial response with a manageable safety profile. Read More ›

Addition of daratumumab to ixazomib/dexamethasone in second-line post-lenalidomide relapsed multiple myeloma (phase 1 portion of the ongoing DARIA study) resulted in a >70% overall response rate. Read More ›

This pivotal trial (OPTIMISMM) subgroup analysis supports use of pomalidomide, bortezomib, and low-dose dexamethasone for lenalidomide-refractory patients regardless of age, prior stem-cell transplant status, or presence of high-risk cytogenetic abnormalities. Read More ›

An observational study of ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma in French centers (REMIX) further defined the patient and disease characteristics and safety profile with this regimen; efficacy data are still maturing. Read More ›

An ongoing study of venetoclax plus daratumumab and dexamethasone ± bortezomib in patients with relapsed/refractory multiple myeloma demonstrated tolerable safety and clinically meaningful overall response rate (92%-96%), particularly among those with t(11;14). Read More ›

In patients with multiple myeloma who undergo frontline optimized induction followed by ASCT, MRD assessment and clinical response time kinetics were predictive of unsustained complete remission, based on a subgroup analysis of PETHEMA/GEM2012MENOS65. Read More ›

Page 2 of 3